Chief Ben-Eghan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chief Ben-Eghan has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Adam S. Butterworth
University of Cambridge
4 shared publications - Carles Foguet
Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
4 shared publications - Scott Callum Ritchie
Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
4 shared publications - Emanuele Di Angelantonio
Human Technopole, Milan, Italy
3 shared publications - Samuel Alec Lambert
Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
3 shared publications - Xilin Jiang
University of Cambridge
3 shared publications
Latest Publications
- Open Access
A proteome-wide association study of cardiovascular diseases in 640,000 participants of multiple ancestries
Proteomics holds great promise for identifying potentially druggable effectors of common diseases, yet its application at population-scale across diverse ancestries, remains challenging. Here, we developed genetic imputation models for 2,594 plasma proteins using proteomic and genetic data from 54,219 UK Biobank participants, validating their performance across multiple ancestry groups and in an independent cohort. Plasma proteomes were then imputed for over 640,000 participants in the UK Biobank and the All of Us Research Program. To assess its aetiological value at population-scale, a further proteome-wide association study of cardiovascular diseases was performed across six genetic ancestries. We identified ∼9000 protein-disease associations across 89 cardiovascular conditions (PheCodes), the majority of which show consistent effects across ancestries and biobanks, with many comprising known targets of drugs either approved or under development. The associations reveal both shared and distinct proteomic signatures across cardiovascular conditions and defined clusters of distinct pathophysiology with shared underlying molecular pathways. Integration of data on tissue specificity and single-cell transcriptomics prioritised liver-derived proteins in circulation as candidate effectors of coronary artery disease, highlighting inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4) as a putative effector. Using a liver-targeted CRISPR gene-editing platform, we show that in vivo disruption of ITIH4 reduces plasma cholesterol and pro-atherogenic lipid species in a preclinical model, consistent with a causal role in cardiovascular disease. Our study enables study of large-scale proteomics in diverse populations, provides a systematic map of protein associations of cardiovascular diseases, and demonstrates the utility of genetically imputed proteomes for target discovery and experimental validation. To facilitate proteomic analyses for the research community, the resultant models and association results have been made freely available through the OmicsPred platform.
Open AccessA proteome-wide association study of cardiovascular diseases in 640,000 participants of multiple ancestries
Proteomics holds great promise for identifying potentially druggable effectors of common diseases, yet its application at population-scale across diverse ancestries, remains challenging. Here, we developed genetic imputation models for 2,594 plasma proteins using proteomic and genetic data from 54,219 UK Biobank participants, validating their performance across multiple ancestry groups and in an independent cohort. Plasma proteomes were then imputed for over 640,000 participants in the UK Biobank and the All of Us Research Program. To assess its aetiological value at population-scale, a further proteome-wide association study of cardiovascular diseases was performed across six genetic ancestries. We identified ∼9000 protein-disease associations across 89 cardiovascular conditions (PheCodes), the majority of which show consistent effects across ancestries and biobanks, with many comprising known targets of drugs either approved or under development. The associations reveal both shared and distinct proteomic signatures across cardiovascular conditions and defined clusters of distinct pathophysiology with shared underlying molecular pathways. Integration of data on tissue specificity and single-cell transcriptomics prioritised liver-derived proteins in circulation as candidate effectors of coronary artery disease, highlighting inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4) as a putative effector. Using a liver-targeted CRISPR gene-editing platform, we show that in vivo disruption of ITIH4 reduces plasma cholesterol and pro-atherogenic lipid species in a preclinical model, consistent with a causal role in cardiovascular disease. Our study enables study of large-scale proteomics in diverse populations, provides a systematic map of protein associations of cardiovascular diseases, and demonstrates the utility of genetically imputed proteomes for target discovery and experimental validation. To facilitate proteomic analyses for the research community, the resultant models and association results have been made freely available through the OmicsPred platform.
- Open Access
Plasma proteomics improves prediction of recurrent cardiovascular events
Background and Aims: Despite treatment, patients with established atherosclerotic cardiovascular disease (ASCVD) are at high risk of recurrent events. Existing clinical risk scores for recurrence provide only moderate predictive performance and rely largely on the same conventional risk factors used to predict disease onset. Proteomics is a promising source of new biomarkers but the technologies need focused use cases in order to achieve utility and implementation. We aimed to determine whether plasma proteomics improves prediction of recurrent cardiovascular events beyond established clinical risk models in secondary prevention in a population-scale cohort. Methods: Plasma proteomic profiles from ∼9,300 participants in the UK Biobank with established ASCVD at baseline were analysed using machine learning methods to derive and evaluate proteomic predictors of recurrent cardiovascular events. The top performing model comprised proteins with non-zero weights (full protein score). Predictive performance of the proteomic predictors, an established clinical risk score (SMART2), and their combination was evaluated across six pre-defined testing datasets representing multiple ethnic and geographic groups. A parsimonious set of proteins with existing clinical-grade enzyme-linked immunosorbent assays (ELISAs) available was then derived. Results: The full protein score achieved higher performance for recurrent ASCVD than the SMART2 risk score across all ethnic and geographic subgroups (mean C-index 0.743 vs 0.653). Adding the full protein score to SMART2 improved discrimination, with the largest increase in White Irish participants (ΔC-index, 0.140; 95% CI, 0.074–0.205; P<0.001). However, adding SMART2 to the protein score provided minimal additional value. The parsimonious score preserved most of the discrimination of the full protein model with C-indices of the recurrent ASCVD risk model comprising age, sex and the parsimonious protein score being nearly identical to the full protein model in the largest testing set (0.723 vs 0.728 for White British in England and Wales). The parsimonious protein score showed a marked gradient of risk with the top, middle and bottom quintiles showing 10-year recurrent ASCVD rates of ∼27.4%, ∼9.6% and ∼2.4%, respectively. Conclusions: In patients with established ASCVD, plasma protein measurements substantially improved prediction of recurrent events beyond conventional clinical risk factors, supporting their potential as a complementary tool to guide secondary prevention of cardiovascular disease.
Open AccessPlasma proteomics improves prediction of recurrent cardiovascular events
Background and Aims: Despite treatment, patients with established atherosclerotic cardiovascular disease (ASCVD) are at high risk of recurrent events. Existing clinical risk scores for recurrence provide only moderate predictive performance and rely largely on the same conventional risk factors used to predict disease onset. Proteomics is a promising source of new biomarkers but the technologies need focused use cases in order to achieve utility and implementation. We aimed to determine whether plasma proteomics improves prediction of recurrent cardiovascular events beyond established clinical risk models in secondary prevention in a population-scale cohort. Methods: Plasma proteomic profiles from ∼9,300 participants in the UK Biobank with established ASCVD at baseline were analysed using machine learning methods to derive and evaluate proteomic predictors of recurrent cardiovascular events. The top performing model comprised proteins with non-zero weights (full protein score). Predictive performance of the proteomic predictors, an established clinical risk score (SMART2), and their combination was evaluated across six pre-defined testing datasets representing multiple ethnic and geographic groups. A parsimonious set of proteins with existing clinical-grade enzyme-linked immunosorbent assays (ELISAs) available was then derived. Results: The full protein score achieved higher performance for recurrent ASCVD than the SMART2 risk score across all ethnic and geographic subgroups (mean C-index 0.743 vs 0.653). Adding the full protein score to SMART2 improved discrimination, with the largest increase in White Irish participants (ΔC-index, 0.140; 95% CI, 0.074–0.205; P<0.001). However, adding SMART2 to the protein score provided minimal additional value. The parsimonious score preserved most of the discrimination of the full protein model with C-indices of the recurrent ASCVD risk model comprising age, sex and the parsimonious protein score being nearly identical to the full protein model in the largest testing set (0.723 vs 0.728 for White British in England and Wales). The parsimonious protein score showed a marked gradient of risk with the top, middle and bottom quintiles showing 10-year recurrent ASCVD rates of ∼27.4%, ∼9.6% and ∼2.4%, respectively. Conclusions: In patients with established ASCVD, plasma protein measurements substantially improved prediction of recurrent events beyond conventional clinical risk factors, supporting their potential as a complementary tool to guide secondary prevention of cardiovascular disease.
- Top Cited PapersOpen Access
- 16 March 2026
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 22 (3) , e1012068
Topological stratification of continuous genetic variation in large biobanks
Biobanks now contain genetic data from millions of individuals. Dimensionality reduction, visualization and clustering are standard when exploring data at these scales; while efficient and tractable methods exist for the first two, clustering remains challenging because of the many ways in which demography and sampling can affect structure. In practice, clustering is commonly performed by drawing shapes around dimensionally reduced data or assuming populations have “type” genomes or allele frequencies that represent a population. We propose to use dimensionality reduction with UMAP followed by clustering with HDBSCAN to identify sets of points forming relatively dense subsets in genotype space. The approach is fast, easy to implement, and integrates with existing pipelines. When applied to simulated data or data from three biobanks, the approach identifies groups of individuals enriched for shared features correlated with ancestry, including country of birth, ethnicity, and sampling location, without requiring strong assumptions about the number or size of clusters, or the sources of population structure. Because it does not rely on proximity to a specific point in genetic space, this topological approach can form clusters that continuously span long distances in genetic space. This can help distinguish admixed populations, which can exhibit wide ancestry variation within populations and overlap of ancestry proportions across populations. Such clusters can highlight and account for interpretable sources of genetic, demographic, or sampling heterogeneity in a dataset that would otherwise have required a range of specialized techniques. We illustrate how topological genetic strata can further help us understand structure within biobanks, evaluate distributions of genotypic and phenotypic data, examine polygenic score transferability, identify potential influential alleles, and perform quality control. Clustering is a common approach to study large-scale genomic datasets. It can be used to investigate the relationships between genetics, demography, and biomedical/environmental variables, as well as defining subgroups for downstream study. Identifying clusters in large biobanks present challenges due to their large size, high dimensionality, and the complexity of the demographic and sampling processes that shape observed genetic diversity. We present a computationally tractable method of clustering using dimensionality reduction (UMAP) and density clustering (HDBSCAN) that captures relatedness patterns and reflects important characteristics of a biobank’s data, even where there are subpopulations of widely varying sizes. This method does not depend on external reference panels, and the clusters can be characterized post hoc using ancestry and ancestry-associated data without using reductive labels. We carry out clustering on simulated data as well as three biobanks and present a series of vignettes showing how clustering helped us identify patterns due to demographic histories and sampling strategy, with an impact on phenotype distributions, genetic risk score accuracy, and data quality control.
- 16 March 2026
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 22 (3) , e1012068
Top Cited PapersOpen AccessTopological stratification of continuous genetic variation in large biobanks
Biobanks now contain genetic data from millions of individuals. Dimensionality reduction, visualization and clustering are standard when exploring data at these scales; while efficient and tractable methods exist for the first two, clustering remains challenging because of the many ways in which demography and sampling can affect structure. In practice, clustering is commonly performed by drawing shapes around dimensionally reduced data or assuming populations have “type” genomes or allele frequencies that represent a population. We propose to use dimensionality reduction with UMAP followed by clustering with HDBSCAN to identify sets of points forming relatively dense subsets in genotype space. The approach is fast, easy to implement, and integrates with existing pipelines. When applied to simulated data or data from three biobanks, the approach identifies groups of individuals enriched for shared features correlated with ancestry, including country of birth, ethnicity, and sampling location, without requiring strong assumptions about the number or size of clusters, or the sources of population structure. Because it does not rely on proximity to a specific point in genetic space, this topological approach can form clusters that continuously span long distances in genetic space. This can help distinguish admixed populations, which can exhibit wide ancestry variation within populations and overlap of ancestry proportions across populations. Such clusters can highlight and account for interpretable sources of genetic, demographic, or sampling heterogeneity in a dataset that would otherwise have required a range of specialized techniques. We illustrate how topological genetic strata can further help us understand structure within biobanks, evaluate distributions of genotypic and phenotypic data, examine polygenic score transferability, identify potential influential alleles, and perform quality control. Clustering is a common approach to study large-scale genomic datasets. It can be used to investigate the relationships between genetics, demography, and biomedical/environmental variables, as well as defining subgroups for downstream study. Identifying clusters in large biobanks present challenges due to their large size, high dimensionality, and the complexity of the demographic and sampling processes that shape observed genetic diversity. We present a computationally tractable method of clustering using dimensionality reduction (UMAP) and density clustering (HDBSCAN) that captures relatedness patterns and reflects important characteristics of a biobank’s data, even where there are subpopulations of widely varying sizes. This method does not depend on external reference panels, and the clusters can be characterized post hoc using ancestry and ancestry-associated data without using reductive labels. We carry out clustering on simulated data as well as three biobanks and present a series of vignettes showing how clustering helped us identify patterns due to demographic histories and sampling strategy, with an impact on phenotype distributions, genetic risk score accuracy, and data quality control.
- Open Access
The genetic determinants of plasma protein variance across ancestries and effects on cardiometabolic disease risk
Variance quantitative trait loci (vQTLs), which capture genetic contributions to phenotypic variability, remain underexplored in proteomic studies, particularly across diverse ancestries. We systematically mapped cis -vQTLs for 2,923 plasma proteins in 52,706 UK Biobank participants of European (EUR, N = 45,486), African (AFR, N = 1,336), and Central/South Asian (CSA, N = 934) ancestries, identifying 2,162 vQTLs (P VE < 5 x 10 -8 ) for 781 proteins. We identified ancestry-specific and shared cis -vQTLs, including those for 30 proteins which were shared across all ancestries, with a few proteins, exhibiting stronger associations in non-EUR ancestry groups despite smaller sample sizes. Across ancestries, 7% (EUR), 25% (AFR), and 14% (CSA) of associations had variance effects only (vQTL only ), lacking corresponding mean effects (P ME > 0.05), with chromosome X enriched for vQTL only associations. Finally, multivariable Mendelian randomization revealed that, independent of genetically predicted mean protein levels, genetically predicted variance of three proteins influenced disease risk of coronary artery disease (Lp(a) and VAMP5) or type 2 diabetes (ANGPTL4). The MR effects for protein levels and variance were independent yet directionally consistent and significant (FDR < 0.05). Taken together, this study identifies novel protein vQTLs, highlights their transferability and demonstrates the potential therapeutic relevance of protein variance.
Open AccessThe genetic determinants of plasma protein variance across ancestries and effects on cardiometabolic disease risk
Variance quantitative trait loci (vQTLs), which capture genetic contributions to phenotypic variability, remain underexplored in proteomic studies, particularly across diverse ancestries. We systematically mapped cis -vQTLs for 2,923 plasma proteins in 52,706 UK Biobank participants of European (EUR, N = 45,486), African (AFR, N = 1,336), and Central/South Asian (CSA, N = 934) ancestries, identifying 2,162 vQTLs (P VE < 5 x 10 -8 ) for 781 proteins. We identified ancestry-specific and shared cis -vQTLs, including those for 30 proteins which were shared across all ancestries, with a few proteins, exhibiting stronger associations in non-EUR ancestry groups despite smaller sample sizes. Across ancestries, 7% (EUR), 25% (AFR), and 14% (CSA) of associations had variance effects only (vQTL only ), lacking corresponding mean effects (P ME > 0.05), with chromosome X enriched for vQTL only associations. Finally, multivariable Mendelian randomization revealed that, independent of genetically predicted mean protein levels, genetically predicted variance of three proteins influenced disease risk of coronary artery disease (Lp(a) and VAMP5) or type 2 diabetes (ANGPTL4). The MR effects for protein levels and variance were independent yet directionally consistent and significant (FDR < 0.05). Taken together, this study identifies novel protein vQTLs, highlights their transferability and demonstrates the potential therapeutic relevance of protein variance.
- Open Access
Multi-ancestry fine-mapping of the chromosome 17q12-q21 asthma locus identifies independent associations implicating lymphocyte and eosinophil levels in the causal pathway
Background: Asthma pathophysiology varies by age-of-onset and involves diverse immune processes reflected in white blood cell (WBC) subsets. To investigate the genetic architecture of asthma and potential endophenotypes, we analyzed the chr17q12-q21 locus, a robustly replicated asthma locus, across European (EUR), African (AFR), East Asian (EAS), and South Asian (SAS) ancestry groups from the UK Biobank (UKB) and Biobank Japan (BBJ). The largest EUR sample was further stratified by age-ofonset as a proxy for etiological heterogeneity. Results: Eight independent asthma signals were identified in UKB-EUR, including two novel associations (Signal 2—rs72832915 and Signal 6—rs507671). Signal 4, corresponding to the originally identified pediatric signal, showed the strongest cross-ancestry evidence, with asthma risk and diminished lymphocyte count co-localizing in three populations. Signal 8 was distinguished by multiple lines of evidence converging on rs112401631 as a likely causal variant, including fine-mapping, colocalization with eosinophil and lymphocyte counts, and mediation of asthma risk through eosinophil count. Signal 6 implicated RARA expression, suggesting vitamin A metabolism impacts on late-onset asthma, the only associated stratum. Notably, integrating WBC traits and Bayesian fine-mapping enabled leveraging non-European ancestry groups to strengthen causal inference despite smaller sample sizes. Conclusion: These findings illustrate how combining age-of-onset stratification, quantitative endophenotypes, and multi-ancestry analyses can reveal mechanistic heterogeneity and prioritize specific variants and path-ways for functional validation. This framework is broadly applicable to complex diseases with measurable quantitative endophenotypes.
Open AccessMulti-ancestry fine-mapping of the chromosome 17q12-q21 asthma locus identifies independent associations implicating lymphocyte and eosinophil levels in the causal pathway
Background: Asthma pathophysiology varies by age-of-onset and involves diverse immune processes reflected in white blood cell (WBC) subsets. To investigate the genetic architecture of asthma and potential endophenotypes, we analyzed the chr17q12-q21 locus, a robustly replicated asthma locus, across European (EUR), African (AFR), East Asian (EAS), and South Asian (SAS) ancestry groups from the UK Biobank (UKB) and Biobank Japan (BBJ). The largest EUR sample was further stratified by age-ofonset as a proxy for etiological heterogeneity. Results: Eight independent asthma signals were identified in UKB-EUR, including two novel associations (Signal 2—rs72832915 and Signal 6—rs507671). Signal 4, corresponding to the originally identified pediatric signal, showed the strongest cross-ancestry evidence, with asthma risk and diminished lymphocyte count co-localizing in three populations. Signal 8 was distinguished by multiple lines of evidence converging on rs112401631 as a likely causal variant, including fine-mapping, colocalization with eosinophil and lymphocyte counts, and mediation of asthma risk through eosinophil count. Signal 6 implicated RARA expression, suggesting vitamin A metabolism impacts on late-onset asthma, the only associated stratum. Notably, integrating WBC traits and Bayesian fine-mapping enabled leveraging non-European ancestry groups to strengthen causal inference despite smaller sample sizes. Conclusion: These findings illustrate how combining age-of-onset stratification, quantitative endophenotypes, and multi-ancestry analyses can reveal mechanistic heterogeneity and prioritize specific variants and path-ways for functional validation. This framework is broadly applicable to complex diseases with measurable quantitative endophenotypes.
- Open Access
Metabolic reaction fluxes as amplifiers and buffers of risk alleles for coronary artery disease
Genome-wide association studies have identified thousands of variants associated with disease risk but the mechanism by which such variants contribute to disease remains largely unknown. Indeed, a major challenge is that variants do not act in isolation but rather in the framework of highly complex biological networks, such as the human metabolic network, which can amplify or buffer the effect of specific risk alleles on disease susceptibility. In our previous work, we established that metabolic models can be leveraged to simulate the emerging metabolic effects of genetically driven variation in transcript levels and estimate personalized metabolic reaction fluxes. Here we use genetically predicted reaction fluxes to perform a systematic search for metabolic fluxes acting as buffers or amplifiers of coronary artery disease (CAD) risk alleles. Our analysis identifies 30 risk locus - reaction flux pairs with significant interaction on CAD susceptibility involving 18 individual reaction fluxes and 8 independent risk loci. Notably, many of these reactions are linked to processes with putative roles in the disease such as the metabolism of inflammatory mediators and fatty acids. In summary, this work establishes proof of concept that biochemical reaction fluxes can have non-additive effects with risk alleles and provides novel insights into the interplay between metabolism and genetic variation on disease susceptibility.
Open AccessMetabolic reaction fluxes as amplifiers and buffers of risk alleles for coronary artery disease
Genome-wide association studies have identified thousands of variants associated with disease risk but the mechanism by which such variants contribute to disease remains largely unknown. Indeed, a major challenge is that variants do not act in isolation but rather in the framework of highly complex biological networks, such as the human metabolic network, which can amplify or buffer the effect of specific risk alleles on disease susceptibility. In our previous work, we established that metabolic models can be leveraged to simulate the emerging metabolic effects of genetically driven variation in transcript levels and estimate personalized metabolic reaction fluxes. Here we use genetically predicted reaction fluxes to perform a systematic search for metabolic fluxes acting as buffers or amplifiers of coronary artery disease (CAD) risk alleles. Our analysis identifies 30 risk locus - reaction flux pairs with significant interaction on CAD susceptibility involving 18 individual reaction fluxes and 8 independent risk loci. Notably, many of these reactions are linked to processes with putative roles in the disease such as the metabolism of inflammatory mediators and fatty acids. In summary, this work establishes proof of concept that biochemical reaction fluxes can have non-additive effects with risk alleles and provides novel insights into the interplay between metabolism and genetic variation on disease susceptibility.
- Open Access
- 1 November 2019
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 15 (11) , e1008432
UMAP reveals cryptic population structure and phenotype heterogeneity in large genomic cohorts
Human populations feature both discrete and continuous patterns of variation. Current analysis approaches struggle to jointly identify these patterns because of modelling assumptions, mathematical constraints, or numerical challenges. Here we apply uniform manifold approximation and projection (UMAP), a non-linear dimension reduction tool, to three well-studied genotype datasets and discover overlooked subpopulations within the American Hispanic population, fine-scale relationships between geography, genotypes, and phenotypes in the UK population, and cryptic structure in the Thousand Genomes Project data. This approach is well-suited to the influx of large and diverse data and opens new lines of inquiry in population-scale datasets. The demographic history of human populations features varying geographic and social barriers to mating. Over time, these barriers have led to varying levels of genetic relatedness among individuals. This population structure is informative about human history, and can have a significant impact on studies of medical genetics. Because population structure depends on myriad demographic, ecological, and social forces, a priori visualization is useful to identify subtle patterns of population structure. We use a dimension reduction method—UMAP—to visualize population structure in three genomic datasets and find previously unobserved patterns, revealing fine-scale population structure and illustrating differences between groups in traits such as white blood cell count, height, and FEV1, a measure of lung function. Using UMAP is computationally efficient and can identify fine-scale population structure in large population datasets. We find it particularly useful to reveal phenotypic variation among genetically related populations, and recommend it is a complement to principal component analysis in primary data visualization.
- 1 November 2019
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 15 (11) , e1008432
Open AccessUMAP reveals cryptic population structure and phenotype heterogeneity in large genomic cohorts
Human populations feature both discrete and continuous patterns of variation. Current analysis approaches struggle to jointly identify these patterns because of modelling assumptions, mathematical constraints, or numerical challenges. Here we apply uniform manifold approximation and projection (UMAP), a non-linear dimension reduction tool, to three well-studied genotype datasets and discover overlooked subpopulations within the American Hispanic population, fine-scale relationships between geography, genotypes, and phenotypes in the UK population, and cryptic structure in the Thousand Genomes Project data. This approach is well-suited to the influx of large and diverse data and opens new lines of inquiry in population-scale datasets. The demographic history of human populations features varying geographic and social barriers to mating. Over time, these barriers have led to varying levels of genetic relatedness among individuals. This population structure is informative about human history, and can have a significant impact on studies of medical genetics. Because population structure depends on myriad demographic, ecological, and social forces, a priori visualization is useful to identify subtle patterns of population structure. We use a dimension reduction method—UMAP—to visualize population structure in three genomic datasets and find previously unobserved patterns, revealing fine-scale population structure and illustrating differences between groups in traits such as white blood cell count, height, and FEV1, a measure of lung function. Using UMAP is computationally efficient and can identify fine-scale population structure in large population datasets. We find it particularly useful to reveal phenotypic variation among genetically related populations, and recommend it is a complement to principal component analysis in primary data visualization.